《新股表現》諾誠健華(09969.HK)開報9.4元 高上市價5%
諾誠健華-B(09969.HK)暗盤收10.22元高上市價14%;該股首掛開報9.4元,較上市價8.95元,高5%,市前成交3,232萬股。
諾誠健華為內地生物醫藥公司。是次來港上市共發售2.5億股,並已引入12名基石投資者合共認購1.25162億股;10%公開發售獲近300倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率25%;股份以招股範圍(8.18-8.95元)上限定價,料集資淨額20.93億元,主要用作核心藥物奧布替尼於內地及美國進行臨床試驗和商業化等工作提供資金、為兩個臨床階段候選產品提供資金、為公司管線中6種IND(臨床研究用新藥或臨床研究用新藥申請)準備階段候選藥物研發提供資金等。上市聯席保薦人分別為大摩及高盛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.